MARKET

AKBA

AKBA

Akebia Therapeut
NASDAQ
1.790
-0.450
-20.09%
Opening 13:35 03/28 EDT
OPEN
2.470
PREV CLOSE
2.240
HIGH
2.470
LOW
1.780
VOLUME
49.14M
TURNOVER
0
52 WEEK HIGH
2.470
52 WEEK LOW
0.4901
MARKET CAP
374.78M
P/E (TTM)
-6.4621
1D
5D
1M
3M
1Y
5Y
Akebia Therapeutics Price Target Raised to $6.00/Share From $5.00 by HC Wainwright & Co.
Dow Jones · 1h ago
Akebia Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1h ago
HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $6
Benzinga · 1h ago
FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia
FDA approves Akebia's Vafseo tablets for anemia due to chronic kidney disease in adults receiving dialysis. The drug is now approved in 37 countries. Approximately 500,000 adult patients in the U.S. On dialysis suffer from anemia.
Benzinga · 3h ago
BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, B Riley, Xilio Therapeutics
Wall Street's main stock indexes set to open flat on Thursday in thin trading ahead of Easter break. Dow e-minis up 0.11%, S&P 500 and Nasdaq 100 down 0.02%. Top three NYSE percentage gainers premarket: Cazoo Group, Xilio Therapeutics. Gold miners rise on U.S. Interest rate cut bets. B Riley Financial up 6.7% in premarket.
Reuters · 4h ago
Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
RH posted weaker-than-expected results for its fourth quarter, but issued upbeat forecast. The company's shares jumped 9.4% to $324.99 in pre-market trading. Avalo Therapeutics, Inc. Gained 256.6% on Wednesday.
Benzinga · 5h ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Avalo Therapeutics (NASDAQ:AVTX) shares rose 328.2% to $20.34 during Thursday's pre-market session. Xilio Therapeutic (XLO) stock moved upwards by 223.94% during the session. Akanda (AKAN) shares increased by 27.1% and INVO Bioscience (INVO) stock increased by 16.36%. NuCana (NCNA) stock declined by 19.8% in the pre- market.
Benzinga · 5h ago
BUZZ-U.S. STOCKS ON THE MOVE-Crypto stocks, Akebia Therapeutics, Sprinklr
U.S. Stock index futures were lackluster on Thursday. Investors await more data to gauge the state of the economy and the Fed's policy path. The top three NYSE percentage gainers premarket were Akebia Therapeutics, Sprinklr. Crypto stocks up as bitcoin, ether prices recover from two-day slide.
Reuters · 5h ago
More
About AKBA
Akebia Therapeutics, Inc. is an integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics that serve as a foundation for future growth. The Company's portfolio includes Auryxia (ferric citrate), Vafseo (vadadustat), and HIF-PH inhibitors. Auryxia is a non-calcium, non-chewable, orally administered tablet, which controls the serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease, (DD-CKD), or the hyperphosphatemia Indication, and the treatment of iron deficiency anemia. Vafseo (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, that is approved in Japan for the treatment of anemia due to chronic kidney disease (CKD), in adult patients. The Company utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Webull offers Akebia Therapeutics Inc stock information, including NASDAQ: AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.